Hosted on MSN18d
Tonix Pharmaceuticals reports positive topline trial outcomes of TNX-1500
Tonix Pharmaceuticals has reported positive topline outcomes from its Phase I single ascending dose study of its crystallisable fragment (Fc)-modified humanised anti-CD40 ligand (CD40L) monoclonal ...
Seeking Alpha29d
Eledon Pharmaceuticals: At The Forefront Of The Organ Transplant Management Business
Eledon Pharmaceuticals' Tegoprubart, a second-gen anti-CD40L antibody, shows promise in preventing organ rejection without thromboembolic risks, addressing unmet needs in kidney and islet cell ...
Taiwan News19d
Tonix Pharmaceuticals Announces Positive Topline Results from Phase 1 Trial for TNX-1500, a Next Generation anti-CD40L mAb Candidate for Prevention of
Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody ...
Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference
Detailed price information for Eledon Pharmaceuticals Inc (ELDN-Q) from The Globe and Mail including charting and trades.